| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1104647446 |
| P356 | DOI | 10.1186/S13045-018-0621-5 |
| P932 | PMC publication ID | 6002979 |
| P698 | PubMed publication ID | 29907126 |
| P2093 | author name string | Michael Wang | |
| Krystle Nomie | |||
| Makhdum Ahmed | |||
| Swathi Balaji | |||
| Fangfang Yan | |||
| Elizabeth Lorence | |||
| P2860 | cites work | The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation | Q22009927 |
| Src-family kinases in B-cell development and signaling | Q24307580 | ||
| BLNK: a central linker protein in B cell activation | Q24322718 | ||
| TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex | Q24329065 | ||
| Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma | Q24613755 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| Regulation of transient receptor potential channels by the phospholipase C pathway | Q26822505 | ||
| Mesalamine in the treatment and maintenance of remission of ulcerative colitis | Q26865546 | ||
| Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases | Q27658863 | ||
| Targeting protein kinase C in mantle cell lymphoma | Q38791124 | ||
| Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma | Q38965699 | ||
| Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma | Q39040982 | ||
| Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. | Q40467188 | ||
| An atypical tumor necrosis factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF family (BAFF) receptor mediates induction of the noncanonical NF-kappaB signaling pathway. | Q40472871 | ||
| Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation | Q40566781 | ||
| Serine 32 and serine 36 of IkappaBalpha are directly phosphorylated by protein kinase CKII in vitro | Q42474454 | ||
| The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target | Q42524101 | ||
| Possible new role for NF-kappaB in the resolution of inflammation. | Q43811439 | ||
| The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status | Q45594007 | ||
| Essential role of MD-2 in LPS responsiveness and TLR4 distribution | Q50109313 | ||
| BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. | Q53664665 | ||
| Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. | Q54648964 | ||
| Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. | Q54986442 | ||
| Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling | Q56897808 | ||
| Unlocking New Therapeutic Targets and Resistance Mechanisms in Mantle Cell Lymphoma | Q57279270 | ||
| Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB | Q64381570 | ||
| B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides | Q81474815 | ||
| Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia | Q27824808 | ||
| Ibrutinib in previously treated Waldenström's macroglobulinemia. | Q27853148 | ||
| Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor | Q28066316 | ||
| Second-generation inhibitors of Bruton tyrosine kinase | Q28076118 | ||
| Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/p100 | Q28216699 | ||
| B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells | Q28245018 | ||
| Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma | Q28263800 | ||
| BCL10 mediates lipopolysaccharide/toll-like receptor-4 signaling through interaction with Pellino2 | Q28589369 | ||
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 | ||
| Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas. | Q30375911 | ||
| Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma | Q33372761 | ||
| Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma | Q33413834 | ||
| Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma | Q33427312 | ||
| NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma | Q33878632 | ||
| Activation of NF-kappaB by FADD, Casper, and caspase-8. | Q33897301 | ||
| Do mantle cell lymphomas have an 'Achilles heel'? | Q34090009 | ||
| Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB. | Q34101051 | ||
| Allergen-induced peribronchial fibrosis and mucus production mediated by IkappaB kinase beta-dependent genes in airway epithelium | Q34202130 | ||
| Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion | Q34415459 | ||
| A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). | Q34663617 | ||
| NF-κB signaling pathways regulated by CARMA family of scaffold proteins | Q35347919 | ||
| Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities | Q35849327 | ||
| Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma. | Q36001708 | ||
| FNC efficiently inhibits mantle cell lymphoma growth | Q36319779 | ||
| Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells | Q36369816 | ||
| Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation | Q36435313 | ||
| The death domain kinase RIP1 is essential for tumor necrosis factor alpha signaling to p38 mitogen-activated protein kinase | Q37057476 | ||
| Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma | Q37076425 | ||
| Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4. | Q37158116 | ||
| Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt | Q37399825 | ||
| MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kappaB proinflammatory responses. | Q37433320 | ||
| Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism. | Q37706550 | ||
| Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis | Q38343572 | ||
| TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy | Q38734433 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 1 | |
| P921 | main subject | mantle cell lymphoma | Q268713 |
| transcription factor | Q407384 | ||
| NF-κB | Q411114 | ||
| signal transduction | Q828130 | ||
| DNA-binding protein | Q2252764 | ||
| nuclear protein | Q16860021 | ||
| P304 | page(s) | 83 | |
| P577 | publication date | 2018-06-15 | |
| P1433 | published in | Journal of Hematology & Oncology | Q15724593 |
| P1476 | title | NF-κB signaling and its relevance to the treatment of mantle cell lymphoma. | |
| P478 | volume | 11 |
| Q92271274 | A novel specific cleavage of IκBα protein in acute myeloid leukemia cells involves protease PR3 |
| Q91627122 | Blockade of IGF2R improves muscle regeneration and ameliorates Duchenne muscular dystrophy |
| Q102071906 | Expression and role of MIG/CXCR3 axis in mantle cell lymphoma |
| Q61805953 | Mantle cell lymphoma and its management: where are we now? |
| Q99622777 | Molecular Pathogenesis of Mantle Cell Lymphoma |
| Q92647353 | Novel immunomodulatory drugs and neo-substrates |
| Q99710790 | PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers |
| Q92568405 | SP/NK-1R promotes gallbladder cancer cell proliferation and migration |
| Q97593212 | Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody |
| Q91660586 | Targeting mTOR for cancer therapy |
| Q92211257 | The Tumor Suppressor, p53, Negatively Regulates Non-Canonical NF-κB Signaling through miRNAInduced Silencing of NF-κB-Inducing Kinase |
Search more.